

What is claimed is,

1. A pharmaceutical dosage form comprising an **undissolved** form of (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl]-amino-1,6-diphenylhexane (ABT-378; lopinavir) in a therapeutically effective amount.
2. The dosage form according to claim 1 further comprising (2S,3S,5S)-5-(N-(N-(N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3hydroxyhexane (ritonavir).
3. The dosage form according to claim 2 wherein the lopinavir and ritonavir are present in the dosage form in a ratio of 4:1.
4. The dosage form according to claim 1 wherein the lopinavir is in an amorphous form.
5. The dosage form according to claim 4 wherein the lopinavir is in a solid dispersion or solid solution.
6. A pharmaceutical dosage form comprising at an undissolved HIV protease inhibitor in a therapeutically effective amount wherein upon administration of a single dose of the protease inhibitor to each member of a study population, the mean of a **AUC_∞** (fed) over **AUC_∞** (fasted) ratio for the members of the study population is in the range of about 0.7 to about 1.43.
7. A pharmaceutical dosage formulation comprising an undissolved HIV protease inhibitor in a therapeutically effective amount wherein upon administration of a single dose of the protease inhibitor to each member of a study **population**, the mean of a **C_{max}** (fed) over C_{max} (fasted) ratio for the members of the study population is in the range of about 0.7 to about 1.43.
8. A pharmaceutical dosage form comprising an undissolved HIV protease inhibitor in a therapeutically effective amount wherein upon **administration** of a single dose of the protease

inhibitor to each **member** of a study **population**, the difference in **AUC_∞** between a 95th **percentile** of the study population and a 5th **percentile** of the study population is less than about 180.

9. A pharmaceutical dosage form comprising an **undissolved HIV** protease inhibitor in a **therapeutically** effective amount wherein upon administration of a single dose of the protease inhibitor to each member of a study population under fasting conditions, the difference in **C_{max}** between the 95th percentile of the study population and the 5th percentile of the study population is less than about 15.

10. The dosage form of any one of claims 6-9 wherein the **HIV** protease inhibitor is **(2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl]-amino-1,6-diphenylhexane (ABT-378; lopinavir);**

11. The dosage form of any one of claims 6-9 wherein the HIV protease inhibitor is **(2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl]-amino-1,6-diphenylhexane (ABT-378; lopinavir)** and said dosage form further comprises **(2S,3S,5S)-5-(N-(N-(N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3hydroxyhexane (ritonavir).**


12. A pharmaceutical dosage form comprising lopinavir **in** a therapeutically effective amount, said dosage form providing an in vitro dissolution profile using a USP apparatus 2 (paddle) at 75 **rpm** with a 0.06M POE10LE (**Polyoxyethylene 10 Lauryl Ether**) medium at **37°C** wherein: about 20 % to about 30 % of lopinavir is released from about 0 to about **15** minutes; about 43 % to about 63 % of lopinavir is released from about 15 to about 30 minutes; about **61.3** % to about **81.7** % of lopinavir is released from about 30 to about 45 minutes; and about 75.4 % to about 93.2 % of lopinavir is released from about 45 to about 60 minutes.

13. A pharmaceutical dosage form comprising ritonavir in a therapeutically effective **amount**, said dosage form providing an in vitro dissolution profile using a USP apparatus 2 (paddle) at 75 rpm with a 0.06M POE10LE (Polyoxyethylene 10 Lauryl Ether) medium at 37°C wherein:

about **19.8** % to about 34.4 % of ritonavir is released from about 0 to about **15** minutes;
about 41.6 % to about 76.5 % of ritonavir is released from about 15 to about 30 minutes;
about 59.4 % to about **91.1** % of ritonavir is released from about 30 to about 45 **minutes**; and
about 73.4 % to about 95 % of ritonavir is released from about 45 to about 60 minutes.

14. A method of treating HIV/AIDS by administering to a **subject** in need thereof the pharmaceutical dosage form of any one of claim **1**.

Dated this 30th day of August 2007 39


Of Anand And Anand Advocates
Attorney for the Applicant